| Name | Title | Contact Details |
|---|
Have your medicine tested at MCR Labs, an ISO-17025 accredited cannabis testing laboratory. We test cannabis products for harmful contaminants and provide cannabinoid profiling. A test requires 0.25 to 0.5 grams flower, 0.1 to 0.2 grams concentrate...
Discover Echo redefines traditional microscope design. Experience our award-winning Automated, Fluorescence, and Transmitted Light Microscopes.
VelosBio Inc. is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. Its lead candidate, VLS-101, is a ROR1-directed ADC being developed for patients with hematologic and solid tumor malignancies. The company is developing a broad pipeline of therapeutics targeting ROR1 in oncologic indications with high unmet medical need.
Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.
We are dedicated to health and to working in consultation with health professionals. We are committed to responsibility, through our secure non-transferable medical cannabis access card system. A system we are establishing in consultation with law enforcement to achieve national recognition.